Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Prothena in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biotechnology company will earn ($3.97) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Prothena's current full-year earnings is ($2.24) per share.
Other research analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and set a $48.00 target price (down previously from $84.00) on shares of Prothena in a research report on Friday, December 20th. StockNews.com lowered Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Chardan Capital started coverage on shares of Prothena in a report on Friday, December 20th. They issued a "buy" rating and a $40.00 price target on the stock. Finally, Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $46.50.
Get Our Latest Research Report on Prothena
Prothena Trading Up 3.3 %
Shares of Prothena stock traded up $0.46 during trading on Wednesday, hitting $14.57. 140,143 shares of the stock were exchanged, compared to its average volume of 427,014. Prothena has a 1-year low of $11.70 and a 1-year high of $34.65. The stock has a market capitalization of $784.01 million, a price-to-earnings ratio of -5.87 and a beta of 0.10. The company has a fifty day moving average price of $14.35 and a 200-day moving average price of $18.04.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. During the same period in the previous year, the firm posted $0.38 EPS. The firm's revenue was down 98.9% compared to the same quarter last year.
Hedge Funds Weigh In On Prothena
Several hedge funds and other institutional investors have recently modified their holdings of PRTA. Ensign Peak Advisors Inc lifted its holdings in shares of Prothena by 30.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 21,643 shares of the biotechnology company's stock valued at $447,000 after buying an additional 5,050 shares during the period. Armistice Capital LLC increased its position in Prothena by 42.3% in the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company's stock worth $32,198,000 after buying an additional 464,000 shares in the last quarter. Algert Global LLC raised its stake in shares of Prothena by 59.7% in the second quarter. Algert Global LLC now owns 77,191 shares of the biotechnology company's stock worth $1,593,000 after buying an additional 28,841 shares during the period. Systematic Financial Management LP lifted its position in shares of Prothena by 25.8% during the 2nd quarter. Systematic Financial Management LP now owns 193,763 shares of the biotechnology company's stock valued at $3,999,000 after buying an additional 39,771 shares in the last quarter. Finally, Duncan Williams Asset Management LLC purchased a new stake in Prothena in the 3rd quarter worth approximately $816,000. 97.08% of the stock is owned by institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
